Men's Health ScreeningNCT07087834
Men's Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening
A study testing CASEM (Cancer Screenings Education for Men) in people with Men's Health Screening and Cancer Screening, run by Pamukkale University at 1 site in Turkey (Türkiye).
Trial summary
Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. Read more about this study
- Who is it for?
- Ages 30 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Men's Health Screening, Cancer Screening
- What is being tested?
- CASEM (Cancer Screenings Education for Men)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2025to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be included in the study, participants must meet all of the following criteria:
- Be 30 years of age or older at the time of the study,
- Be at least literate,
- Have no cognitive, visual, or orthopedic impairments that would prevent them from completing the questionnaires,
- Be able to speak and understand Turkish,
- Have no previous history of cancer diagnosis or cancer treatment,
- Agree to participate in the study.
Who cannot join
- Participants are excluded from the study if they meet any of the following criteria:
- Having previously had cancer and undergone cancer treatment,
- Not currently employed at the institution (e.g., on temporary assignment),
- Refusing to participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Education Given to Men on Their Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening
Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. According to GLOBOCAN 2022 data, more than 51% of all cancer cases worldwide occur in men. The three most common types of cancer in men are lung cancer, prostate cancer, and colorectal cancer. Increasing awareness, attitudes, and knowledge levels regarding cancer screenings, especially for preventable diseases, will increase participation in screening programs. Increased knowledge levels will translate into positive health behaviors. This study will be conducted as a randomized controlled trial to determine the effect of the Cancer Screenings Education for Men (CASEM) intervention on men's perceptions, attitudes, and knowledge regarding cancer screening programs. Research data will be collected at a public institution between September 2025 and September 2026. The study sample will consist of a total of 78 male individuals, including 39 experimental and 39 control groups that meet the inclusion criteria. Male individuals will be assigned to the experimental and control groups using stratified randomization. The Individual Identification Form, Cancer Screening Perception Scale, Cancer Screening Attitude Scale, and Cancer Screening Knowledge Scale will be used. IBM SPSS 29.0 software will be used to analyze the data obtained from the study. This study will be an important one that addresses Turkey's future vision within the scope of the Twelfth Development Plans and supports the goals and policy measures of the development plan. In addition, our study serves the Sustainable Development Goals, which are among the most important global goals in the context of sustainability. It is expected to have implications for health practices and planning.
- Conditions
- Men's Health Screening, Cancer Screening
- Being tested
- CASEM (Cancer Screenings Education for Men)
- Keywords
- Men's Health, Early Detection of Cancer, Screening
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CASEM (Cancer Screenings Education for Men)Other
Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session.
Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Not described Receives: Other: CASEM (Cancer Screenings Education for Men) |
| Control Group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change in the cancer screening perception of the experimental group according to the Cancer Screening Perception Scale scores at the end of the first and third month
It is a 26-item scale developed by Mahmood et al. (2016). Its validity and reliability in Turkish were established by Bozkurt and Yılmaz (2024). The scale items generally cover. The scale has five sub-factors: "Perceived Severity, Perceived Sensitivity, Perceived Benefits, Perceived Barriers, and Action Cues." The scale is a 6-point Likert scale (1 = Strongly disagree, 6 = Strongly agree). To prevent confusion, there is no "undecided" option. The scale is not aggregatable, and each sub-dimension in the scale is evaluated separately.
Measured: 3 months
The change in the cancer screening attitude of the experimental group according to the Cancer Screening Attitude Scale scores at the end of the first and third month
The scale was developed by Yıldırım-Öztürk and colleagues (2020). The scale consists of 24 items and a single dimension. The scale is a five-point Likert scale. The items comprising the scale are answered on a scale ranging from 5 to 1, as follows: "5: I completely agree, 4: I somewhat agree, 3: I neither agree nor disagree, 2: I somewhat disagree, 1: I completely disagree." The scale is suitable for use on women and men aged 30-70 who are at least literate and do not have cognitive, visual, or orthopedic impairments that would prevent them from completing the scale.
Measured: 3 months
The change in the cancer screening knowledge of the experimental group according to the Cancer Screening Knowledge Scale scores at the end of the first and third month
The scale was developed by Yıldırım-Öztürk and Uyar (2023). The scale consists of 25 items and 3 subscales. The subscales of the scale have not been specifically named. The first subscale of the scale consists of 10 items (items 8, 17-23, 25, and 28), the second subscale consists of 9 items (items 4, 5, 7, 10, 12, 13, 15, 16, and 27), and the third subscale has 6 items (items 1-3, 9, 11, 24). The scale is a three-point rating scale. The scale is answered on a scale from 1 to 3, with "1: Correct, 2: Incorrect, 3: I don't know." When calculating the scale score, "True" responses are scored as 1 point, while 'False' and "I don't know" responses are scored as 0 points. The lowest possible score on the scale is 0, and the highest possible score is 25. When calculating the scale score, the three items with negative meanings (Items 2, 11, and 24) must be reverse-coded. No cutoff point has been established for the scale score.
Measured: 3 months
Secondary outcomes (1)
Individuals' status regarding cancer screening in the final test conducted at the end of the third month after education
Both groups will be asked whether they conducted cancer screening in their final tests. A single-question survey will be administered, asking, "Have you had a cancer screening in the last three months?" Responses will be evaluated on a two-point Likert scale, with options for 'yes' and "no."
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start1 Sep 2025
- Primary completion30 Sep 2025
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Men's Health ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The final tests (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session. Content and Materials of the Training to be Provided to the Experimental Group The CASEM intervention will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. CASEM covers basic information about cancer, common types of cancer among men, screening
- Masking
- None (open label)
- Enrolment
- 78 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pamukkale University
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Principal investigator, Edanur Özkaya Bozkurt, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07087834
- Sponsor's protocol ID
- E-60116787-020-683945
- Status last verified
- Sep 2026
- First submitted
- 4 Jul 2025
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD will share.
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Education Given to Men on Their Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening
- ClinicalTrials.gov ID
- NCT07087834
- Acronym / sponsor ID
- E-60116787-020-683945
- Conditions
- Men's Health Screening, Cancer Screening
- Keywords
- Men's Health, Early Detection of Cancer, Screening
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 78 participants (actual)
- Lead sponsor
- Pamukkale UniversityUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 28 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. According to GLOBOCAN 2022 data, more than 51% of all cancer cases worldwide occur in men. The three most common types of cancer in men are lung cancer, prostate cancer, and colorectal cancer. Increasing awareness, attitudes, and knowledge levels regarding cancer screenings, especially for preventable diseases, will increase participation in screening programs. Increased knowledge levels will translate into positive health behaviors. This study will be conducted as a randomized controlled trial to determine the effect of the Cancer Screenings Education for Men (CASEM) intervention on men's perceptions, attitudes, and knowledge regarding cancer screening programs. Research data will be collected at a public institution between September 2025 and September 2026. The study sample will consist of a total of 78 male individuals, including 39 experimental and 39 control groups that meet the inclusion criteria. Male individuals will be assigned to the experimental and control groups using stratified randomization. The Individual Identification Form, Cancer Screening Perception Scale, Cancer Screening Attitude Scale, and Cancer Screening Knowledge Scale will be used. IBM SPSS 29.0 software will be used to analyze the data obtained from the study. This study will be an important one that addresses Turkey's future vision within the scope of the Twelfth Development Plans and supports the goals and policy measures of the development plan. In addition, our study serves the Sustainable Development Goals, which are among the most important global goals in the context of sustainability. It is expected to have implications for health practices and planning.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The final tests (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session. Content and Materials of the Training to be Provided to the Experimental Group The CASEM intervention will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. CASEM covers basic information about cancer, common types of cancer among men, screening
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Other: CASEM (Cancer Screenings Education for Men) |
| Control Group | No intervention | – |
Who may qualify
- Ages
- 30 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Be 30 years of age or older at the time of the study,
- Be at least literate,
- Have no cognitive, visual, or orthopedic impairments that would prevent them from completing the questionnaires,
- Be able to speak and understand Turkish,
- Have no previous history of cancer diagnosis or cancer treatment,
Key exclusion criteria (4 listed)
- Having previously had cancer and undergone cancer treatment,
- Not currently employed at the institution (e.g., on temporary assignment),
- Refusing to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CASEM (Cancer Screenings Education for Men)Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session. Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo | Other | Experimental group |
Primary outcome
The change in the cancer screening perception of the experimental group according to the Cancer Screening Perception Scale scores at the end of the first and third month
Time frame: 3 months
It is a 26-item scale developed by Mahmood et al. (2016). Its validity and reliability in Turkish were established by Bozkurt and Yılmaz (2024). The scale items generally cover. The scale has five sub-factors: "Perceived Severity, Perceived Sensitivity, Perceived Benefits, Perceived Barriers, and Action Cues." The scale is a 6-point Likert scale (1 = Strongly disagree, 6 = Strongly agree). To prevent confusion, there is no "undecided" option. The scale is not aggregatable, and each sub-dimension in the scale is evaluated separately.
The change in the cancer screening attitude of the experimental group according to the Cancer Screening Attitude Scale scores at the end of the first and third month
Time frame: 3 months
The scale was developed by Yıldırım-Öztürk and colleagues (2020). The scale consists of 24 items and a single dimension. The scale is a five-point Likert scale. The items comprising the scale are answered on a scale ranging from 5 to 1, as follows: "5: I completely agree, 4: I somewhat agree, 3: I neither agree nor disagree, 2: I somewhat disagree, 1: I completely disagree." The scale is suitable for use on women and men aged 30-70 who are at least literate and do not have cognitive, visual, or orthopedic impairments that would prevent them from completing the scale.
The change in the cancer screening knowledge of the experimental group according to the Cancer Screening Knowledge Scale scores at the end of the first and third month
Time frame: 3 months
The scale was developed by Yıldırım-Öztürk and Uyar (2023). The scale consists of 25 items and 3 subscales. The subscales of the scale have not been specifically named. The first subscale of the scale consists of 10 items (items 8, 17-23, 25, and 28), the second subscale consists of 9 items (items 4, 5, 7, 10, 12, 13, 15, 16, and 27), and the third subscale has 6 items (items 1-3, 9, 11, 24). The scale is a three-point rating scale. The scale is answered on a scale from 1 to 3, with "1: Correct, 2: Incorrect, 3: I don't know." When calculating the scale score, "True" responses are scored as 1 point, while 'False' and "I don't know" responses are scored as 0 points. The lowest possible score on the scale is 0, and the highest possible score is 25. When calculating the scale score, the three items with negative meanings (Items 2, 11, and 24) must be reverse-coded. No cutoff point has been established for the scale score.
1 secondary outcome
Individuals' status regarding cancer screening in the final test conducted at the end of the third month after education
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: Yes. All collected IPD will share.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CASEM (Cancer Screenings Education for Men) in people with Men's Health Screening and Cancer Screening, run by Pamukkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change in the cancer screening perception of the experimental group according to the Cancer Screening Perception Scale scores at the end of the first and third month (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.